admin

With a swell of R&D activity flowing into the development of cell and gene therapies over the past decade, a manufacturing shortage gripped the industry. This caused industry participants to express grave fears that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these new types of living therapies

È di pochi giorni fa la notizia dell’approvazione negli Stati Uniti di una terapia genica per l’atrofia muscolare spinale

Bluebird Bio Inc.’s first gene therapy, a treatment for an inherited blood disorder, was cleared by European Union regulators, another milestone for the field following U.S. approval of Novartis AG’s $2.1 million treatment for a lethal childhood disease

A comprehensive guide to Europe’s growing advanced therapies and viral vector manufacturing landscape

CRO, CMO, CDMO. These acronyms are well known in the biotech and pharma industry. But what is a BMO? If you haven’t heard of it, don’t worry. After all, there is only one BMO worldwide. We have set out to discover more about it, this biotech manufacturing organization

L’Italia come Hub internazionale per le terapie avanzate. Uno scenario di sfide e opportunitá